Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.

Acta oncologica (Stockholm, Sweden) - 1 Dec 2023

Skribek Marcus, Brunnström Hans, Oskarsdottir Gudrun, Portu Grivé Mikel, Aricak Ozan, Planck Maria, Jatta Kenbugul, Naserhojati Homeyra, Haglund de Flon Felix, Ekman Simon

Abstract excerpt

BACKGROUND: Real-World evidence on mesenchymal-epithelial transition exon 14 skipping mutations (METex14) in lung cancer remains limited. With an incidence of 3-4% across histological subtypes, METex14 is now an actionable target for MET inhibitors (METi) in advanced lung cancer, demonstrating response rates between 30-70%. Yet, its role in early stages and sensitivity to immune checkpoint inhibitors (ICIs) is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hospitals, University

Share to Lung Neoplasms

Share to Mutation

Share to Sweden

Source

Identifiers

PMID: 37897706
DOI: 10.1080/0284186X.2023.2269310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world analysis of MET exon 14 mutations in non-small cell lung cancer: a retrospective study from two Swedish hospitals.PMID 37897706Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.Semantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.Semantic proximity Read ↗

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.Semantic proximity Read ↗

Real world experience with MET inhibitors in MET exon 14 skipping mutated non-small cell lung cancer: largest Indian perspectiveSemantic proximity Read ↗

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.Semantic proximity Read ↗

Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.Semantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective.Semantic proximity Read ↗

Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.Semantic proximity Read ↗

Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.